Aberrant activation in fibroblast growth factor signaling has been implicated in the
development of various cancers, including squamous cell lung cancer, squamous cell head …

Therapies that target the EGF receptor (EGFR), such as gefitinib (IRESSA), are effective in a
subset of patients with advanced non-small cell lung cancer (NSCLC). The differences in …

Cancer cell resistance arises when tyrosine kinase inhibitor (TKI)-targeted therapies induce
a drug-tolerant persister (DTP) state with growth via genetic aberrations, making DTP cells …

Cancer treatment decisions are increasingly guided by which specific genes are mutated
within each patient's tumor. For example, agents inhibiting the epidermal growth factor …

Objective: Dysfunction in fibroblast growth factor receptor (FGFR) signaling has been
reported in diverse cancer types, including non-small cell lung cancer (NSCLC). The …

Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non–small
cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified …

The overall power of kinase inhibitors is substantially overshadowed by the acquisition of
drug resistance. To address this issue, we systematically assessed the potential of secreted …

The MET receptor tyrosine kinase is often deregulated in human cancers and several MET
inhibitors are evaluated in clinical trials. Similarly to EGFR, MET signals through the RAS …

EGFR tyrosine kinase inhibitors have shown promising efficacy in the treatment of tumors
with EGFR mutations and amplifications. However, tyrosine kinase inhibitors have also …

Frequent genetic alterations discovered in FGFRs and evidence implicating some as drivers
in diverse tumors has been accompanied by rapid progress in targeting FGFRs for …